Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas
Status:
Completed
Trial end date:
2017-09-19
Target enrollment:
Participant gender:
Summary
The NOA-16 trial is the first-in-man trial of the IDH1 (isocitrate dehydrogenase type 1)
peptide vaccine targeting the IDH1R132H mutation (amino acid exchange from arginine to
glutamine at position 132 of IDH1). The aim of this trial is to evaluate the safety and
tolerability of and immune response to the IDH1 peptide vaccine in patients with
IDH1R132H-mutated, WHO grade III-IV gliomas.
Phase:
Phase 1
Details
Lead Sponsor:
National Center for Tumor Diseases, Heidelberg
Collaborators:
German Cancer Research Center Neuro-Oncology Working Group of the German Cancer Society University Hospital Heidelberg